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ABSTRACT 
PLGA (poly D,L-lactic-co-glycolic acid) nanoparticles (NPs) encapsulating 
magnetite nanoparticles (MNPs) along with a model drug human serum albumin (HSA) 
were prepared by double emulsion solvent evaporation method. This part I will focus on 
size and size distribution of prepared NPs whereas encapsulation efficiency will be 
discussed in part II. It was found that mean hydrodynamic particle size was influenced by 
five important process variables. To explore their effects, a 5-factorial 3-level 
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experimental design and statistical analysis were carried out using STATISTICA® 
software. Effect of process variables on the mean size of nanoparticles was investigated 
and finally conditions to minimize size of NPs were proposed. GAMS™/MINOS 
software was used for optimization. The mean hydrodynamic size of nanoparticles ranged 
from 115-329 nm depending on the process conditions. Smallest possible mean particle 
size can be achieved by using low polymer concentration and high dispersion energy 
(enough sonication time) along with small aqueous/organic volume ratio.  
 
Keywords: PLGA (poly D,L-lactic-co-glycolic acid); albumin; encapsulation. 
____________________________________ 
* Correspondance: Quazi T. H. Shubhra; email: shubhro.du@gmail.com;  
Fax:+36-88624038 ; Tel : +36204843689. 
 
INTRODUCTION 
Nanotechnologies are wide spread in medical sciences and pharmaceutical 
industries, namely in controlled drug delivery and disease detection. Nanoparticles 
designed for drug delivery should be above all biocompatible and biodegradable (Gupta 
et al. 2005; Xie et al. 2006). The aim of targeted drug delivery and therapy is to transport 
a drug directly to the disease loci with no or minimal side effects on the human body 
(Chomoucka et al. 2010). The potential of drug delivery systems based on the use of 
nanoparticles offer three major significant advantages: (i) the ability to target specific 
locations in the body, (ii) the reduction of the drug quantity needed to attain a particular 
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concentration in the vicinity of the target and (iii) the reduction of the drug concentration 
at non-target sites which minimizes severe side effects (Arruebo et al. 2007). 
Poly(D,L-lactic-co-glycolic acid) (PLGA) is a biocompatible (non-toxic) and 
biodegradable material often used for preparing nano- and microparticles (Zimmer et al. 
1995; Bala et al. 2004). During the last two decades, PLGA has attracted considerable 
attention due to its excellent drug loading capacity. Drug-loaded PLGA nanoparticles 
have been extensively studied in the pharmaceutical and medical fields. Many PLGA-
based nanoformulations have reached different stages of preclinical development, 
although they still present distinct challenges for researchers. 
Most of the research on magnetic nanoparticles for clinical applications has 
focused on iron oxide nanoparticles such as magnetite (Fe3O4) or maghemite (γ-Fe2O3) 
due to their biological compatibility and FDA approval for clinical usage (Weissleder et 
al. 1989; Ibrahim et al. 1983; Muller et al. 1996). Oleic acid coated Fe3O4 was selected in 
this study because it is well dispersible in organic media. 
Human serum albumin (HSA) is used as a model drug in this study which is a 
monomeric multi-domain macromolecule. It is the most abundant plasma protein in the 
human body with a plasma concentration of 0.6 mM (Yang et al. 2007). HSA consists of 
585 amino acids that form into three structurally similar α-helical domains (Yan et al. 
2009).  
Organic solvent dichloromethane (DCM) has the ability to dissolve a wide range 
of organic compounds including PLGA. DCM is volatile at room temperature and 
evaporates very quickly. It can be removed completely by evaporation from a mixture by 
mechanical stirring. PVA is the most commonly used emulsifier in the formulation of 
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PLGA nanoparticles (Sahoo et al. 2002). Insufficient amount of the emulsifier fails to 
stabilize the emulsion, and thus form particles which tend to aggregate. 
Some of the common methods to prepare nanoparticles loaded with low-
molecular-weight drugs include w/o single emulsification (Niwa et al. 1995), o/w single 
emulsification (Saxena et al. 2004; Tewes et al.  2007), nanoprecipitation (Barichello et al. 
1999; Bilati et al. 2005) and w/o/w double emulsification (Dillen et al. 2006; Ubrich et al. 
2004; Song et al. 2008). Among them, double emulsion method was selected in this study. 
Although single emulsion method is simpler than double emulsion method, it cannot be 
used for studying the applied three phase system. Because of their compartmentalized 
internal structure, double emulsions can provide advantages over simple o/w emulsions, 
especially for encapsulation (Hanson et al. 2008). Double emulsification method has 
some other advantages e.g. nanoparticle size can be controlled by changing several 
process parameters and purity of nanoparticles is satisfactory. 
Till now, very few works have been published on HSA encapsulation by using 
PLGA matrix. Moreover, co-encapsulation of HSA or other protein drugs along with 
magnetic nanoparticles is rarely studied in literature. Size is one of the most important 
factors for drug-loaded NPs, especially if they are intended for administration by 
injection. NP size is also crucial to drug release behavior (Wei et al. 2008). Production of 
spherical particles < 220 nm with a narrow size distribution and without agglomeration 
has significance in injection drug formulations, allowing sterilization of the product by 
ultra-filtration via a membrane with 220 nm cut-off value (Feczko et al. 2011). 
The observed influences of process variables on the mean size of the resulted 
PLGA nanoparticles are in good agreement with the earlier works of Feczkó et al. 
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(Feczko et al. 2011). In that work, the authors encapsulated bovine serum albumin (BSA) 
into PLGA nanoparticles applying similar conditions and using double emulsion solvent 
evaporation process. The difference is that study involves BSA encapsulation instead of 
HSA and the effect of PVA concentration in the external aqueous phase was examined in 
that study, but no magnetic nanoparticles and their encapsulation were involved in the 
study of Feczkó et al. (Feczko et al. 2011). Vankova et al. (Vankova et al. 2007) studied 
five process parameters as our work does to predict the droplet size of liquid-liquid 
emulsions, although the parameters are different. The main difference between their 
study and our work is that we used “ultrasonicator” to produce double emulsion and solid 
nanocapsules were prepared. But Vankova et al. applied a “narrow-gap homogenizer” to 
produce simple emulsion droplets. Davies et al. (Davies et al. 1985) studied the 
comparison of droplet sizes with rates of turbulent energy dissipation in various types of 
practical equipments. The calculations done by the authors support the mechanism of 
drop break-up. Our findings comply with both Vankova et al. and Davies et al. e.g. 
because viscosity of the oil phase influenced our particle size, as it was the case with the 
droplets prepared by them. 
The aim of this study was to prepare PLGA nanoparticles by double emulsion 
solvent evaporation method with narrow size distribution. Due to experimental design 
(made by STATISTICA® software), it was possible to explore precisely the influence of 
different parameters and their combined influences. GAMS™/MINOS software was used 
for optimization which gave precise result. Earlier no comprehensive studies were carried 
out to understand the particular effect of the studied five parameters and process 
conditions on the final sizes of PLGA nanoparticles and no research was carried out on 
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co-encapsulation of HSA and oleic acid coated magnetite by PLGA (the encapsulation 
efficiency is discussed in part II) which for sure makes this novel study not only 
interesting but also creates scope for further research and innovation. The outcome of this 
study will give us the ideal combination of variables to get desired size of model drug-
loaded PLGA nanoparticles which will be exploited with the real drug for further 
innovation in the field of targeted drug delivery. 
MATERIALS AND METHODS 
Materials 
PLGA (50:50, Mw = 8,000, Resomer
® RG 502H) containing free carboxyl end-
groups was a gift of Boehringer Ingelheim, Germany. HSA solution was obtained from 
Trigon Biotechnological Ltd., Hungary. The concentration of bulk HSA solution was 
36.87 g/L. Poly(vinyl alcohol) (PVA; Mw = 30,000–70,000) and phosphate-buffered 
saline (PBS, pH 7.4) were purchased from Sigma-Aldrich. Dichloromethane (DCM) was 
purchased from Spektrum-3D, Hungary. Magnetite was synthesized by co-precipitation 
method. 
Synthesis of oleic acid-coated superparamagnetic iron oxide nanoparticles dispersed in 
organic media  
Neat superparamagnetic nanoparticles were prepared by coprecipitation of Fe(II) 
and Fe(III) chlorides in aqueous ammonia solution by modification of an earlier 
published method (Horak et al. 2003). Briefly, FeCl3·6H2O (24.32 g) and 11.92 g of 
FeCl2·4H2O (molar ratio 2:1) were stirred at 400 rpm in Q-water (50 ml) under nitrogen 
atmosphere. To this solution, 28% NH4OH solution (50 ml; 50% excess) was added over 
a period of 20–30 min. To coat the nanoparticles, oleic acid (5 ml) was added to the 
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reaction mixture at 90°C and the reaction proceeded for 5 h until the NH3 odor 
disappeared. After cooling to room temperature, the nanoparticles were washed with Q-
water for 4 days (three times 200 ml of water a day). The magnetite particles were 
separated by a magnet, decanted, washed with water and dried at 80°C and 13 Pa to yield 
about 16 g of product. Finally, the particles were under sonication resuspended in 
dichloromethane to a concentration of 1.92 wt% Fe3O4. The size of the core of prepared 
magnetite NPs was 10 ± 5 nm. 
Nanoparticle preparation 
Nanoparticles were prepared by double emulsion solvent evaporation method 
(Feczko et al. 2008; Panyam et al. 2003) shown schematically in Fig. 1. At first PLGA 
(0.05-0.2 g) was dissolved in DCM using magnetic stirrer. Fe3O4 (1 to 20% by weight 
related to the weight of PLGA) was added to the system and sonicated with a Model W-
220 probe sonicator (Heat Systems-Ultrasonics) for 30 s. The power of sonicator was 70 
W, frequency 20 kHz and probe type was “H-I” type. The total volume of DCM in the 
system was fixed at 5 ml. Then 0.5 ml model drug solution of preset concentration, 
diluted with PBS, was added to the system and the two-phase system was emulsified for 
60 s using the same sonicator which resulted in w/o emulsion. This emulsion was 
dispersed in the outer water phase containing 2 wt% PVA (10-30 ml) using the same 
sonicator for 1-3 min to obtain w/o/w double emulsion. The DCM was evaporated to 
solidify PLGA NPs under continuous stirring (800 rpm) for 2 h using a magnetic stirrer. 
After the evaporation of DCM, dispersed solid PLGA NPs with encapsulated model drug 
and Fe3O4 were obtained and stored for further experimental analysis. Sonication process 
was always carried out in an ice bath. Utilization of an ultrasonic probe leads to an 
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increase in bulk temperature. If the temperature is not controlled using ice bath, some 
undesired effects may occur. The most obvious is the degradation of compounds of 
interest. In addition, as the temperature is increased, the physical characteristics of the 
liquid media change in such a way that the ultrasonic transmission can be affected and no 
cavitation is achieved. This phenomenon is known as “decoupling” (Santos et al. 2009).  
Fig. 1. 
Hydrodynamic size analysis  
Hydrodynamic diameter and the size distribution of the resulted particles were 
analyzed by dynamic light scattering (DLS) method (also called as photon correlation 
technique) using Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) at 25°C. For 
each sample, five parallel size measurements were carried out.  
Experimental design 
To elucidate the effect of process conditions on the mean hydrodynamic particle 
size and to decrease the number of the studied parameter combinations and thus the 
number of experiments, a 3(p-1) type fractional factorial experimental design was carried 
out using STATISTICA® (version 10.0, StatSoft Inc., USA) software, where “p” is the 
number of factors (variables). The obtained experimental data were evaluated by 
statistical analysis, similarly to the method described by Feczkó et al. (Feczko et al. 2011) 
for bovine serum albumin encapsulated in PLGA nanoparticles and Biró et al. (Biro et al.  
2009) for chitosan microparticles. 
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According to preliminary tests, five process variables summarized in Table 1 
(factors F1–F5) were selected, which strongly influenced the hydrodynamic particle sizes 
and/or the encapsulation process. These variables are the amount of iron oxide in the 
organic phase (F1) relative to the weight of PLGA used for encapsulation, concentration 
of PLGA in the organic phase (F2), concentration of HSA in the inner aqueous phase 
(F3), the outer aqueous/organic phase volume ratio (F4), and time of the ultrasonic 
treatment in the second emulsification (F5). 
Table 1. 
As a result of the experimental design (DOE), 3(5-1) = 81 experiments were needed 
without repetitions due to variation of five variables. However, to estimate the pure error, 
9 repetitions of experiments were also carried out.  This resulted in 90 experiments 
altogether. For each variable 3 different levels (the lowest, mean and highest) were taken 
into consideration. The main advantage of applying experimental design was the vast 
reduction of the experimental work without remarkable loss of useful information. 
Without this, it would be needed to perform 35 = 243 experiments. The experimental 
program determined by STATISTICA® (including the repetition) is not shown in the 
manuscript. first six columns of the table in Appendix A. From the table it is seen that 
repetitions were carried out at the central point of each variable intervals indicated by C 
with bold numbers. In the second last column of the table, the measured mean particle 
sizes are listed. In the last column of that table, encapsulation efficiency of model drug is 
listed which will be discussed in detail in our following paper (Part II). 
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Optimization of the result 
In certain applications, such as production of injectable drug formulations, the 
smallest possible particle size should be achieved, which obviously depends on the 
process variables. Due to high number of variables, it was necessary to determine the 
optimum process conditions mathematically to achieve desirable nanosized PLGA 
capsules. For this purpose the GAMS™/MINOS Large Scale Nonlinear Solver for 
Windows Ver. 5.51 (System Optimization Laboratory, Stanford University) software was 
applied. The software is able to optimize the variables by precise mathematical 
procedures. 
 
RESULTS AND DISCUSSION 
The influencing variables were systematically changed according to the research 
plan determined by the scheme obtained from the DOE. During this study, the measured 
size distributions and mean hydrodynamic particle sizes showed characteristic variations 
depending on the values of independent variables applied in the different experiments. 
Fig. 2 shows typical particle size distributions selected from the 90 experiments, with 
various resulted size ranges corresponding to relatively low, medium and high mean 
particle sizes. It is seen that the studied process variables, such as PLGA concentration in 
the intermediate organic phase, or the time of the second sonication influenced strongly 
the obtained size distribution and the mean particle size. For example, low PLGA 
concentration and long sonication time resulted in smaller mean particle sizes, while high 
PLGA concentration and short ultrasound treatment during the second emulsification 
gave larger particle sizes. So, with the increase in PLGA concentration value from low to 
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high, size distribution changes follow the order a to c in Fig. 2 whereas with the decrease 
in PLGA concentration, reverse change is observed i.e. from c to a in Fig. 2. Opposite 
trend has been observed for the variable sonication time and shown in the same Fig. 
These diagrams show smooth and quite regular curves similar to the usual lognormal 
distribution. The dependence of the mean hydrodynamic particle size on the process 
parameters offers good opportunity for optimization. Therefore statistical evaluation on 
the effect of different variables, and process optimization have been carried out for this 
purpose. 
Fig. 2.a, b, c 
As a result of the statistical analysis, the significance and importance of the 
studied variables influencing the mean hydrodynamic particle size was characterized by 
ANOVA table (Table 2) and Pareto chart of the standardized effects. From Table 2 it is 
seen that four factors F1, F2, F4 and F5 (i.e. the relative amount of magnetite, the PLGA 
concentration, the external aqueous/intermediate organic phase volume ratio, and 
sonication time, respectively), and the interaction of factors F1 and F4 show statistically 
significant influences, all of them having much lower p values than the widely accepted 
significance level (p = 0.05). Table 2 also shows that the mean square of residuals (MS) 
was 762.37 nm2, i.e. the mean deviation between the measured and estimated mean 
particle sizes is 6.2737.762 =  nm, which was considered acceptable by us. The 
histogram of residual (not presented here) values showed almost normal distribution. 
Therefore the estimation made by the multivariable regression was accepted. The pure 
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error of experimental data determined from the 9 repeated runs was 5.133.181 = nm, 
which provides reasonable accuracy. 
Table 2. 
The Pareto chart (Fig. 3) shows that mean hydrodynamic size was affected most 
strongly by PLGA concentration (F2) followed by the duration of ultrasonic treatment 
(F5). Iron oxide/PLGA weight ratio (F1), volume ratio (F4), and the linear-linear 
interaction of the latter factors (F1L×F4L) also played significant roles. Letter “L” on the 
scale of the diagram refers to the linear correlation between the given variable and the 
dependent variable (the mean hydrodynamic particle size). Among the studied five 
variables, the concentration of HSA in the inner aqueous phase (F3) has no significant 
influence on particle size although this variable has strong influence on encapsulation 
efficiency as will be found in our following paper (Part II). 
Fig. 3. 
As a result of the statistical analysis, a regression equation was obtained by which 
the dependence of the mean hydrodynamic particle size Dmean can be estimated for 
various combinations of the studied independent variables: 
667.143XX7796.0X6089.18X5864.12X088.16X7097.4D VOLR4O3FetimeVOLRPLGA4O3Femean +⋅⋅−⋅−⋅+⋅+⋅=  (1)  
The effects of the process variables on the predicted mean hydrodynamic particle size are 
demonstrated in Fig. 4-6 and discussed below. 
Effect of Fe3O4/PLGA weight ratio 
Page 12 of 41
URL: http://mc.manuscriptcentral.com/tmnc  Email: microencapsulation@hotmail.co.uk
Journal of Microencapsulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 13
As can be seen from the 3D diagram of Fig. 4(a), the increase in the relative 
amount of the Fe3O4 nanoparticles (relative to the weight of PLGA) dispersed in the 
intermediate organic phase (DCM), caused considerable increase in the mean particle size 
of the final NPs. At medium values of the three other variables (HSA concentration, w/o 
volume ratio, and sonication time) the predicted (using equation 1, for 1% PLGA) mean 
particle size of the composite PLGA nanoparticles increases from 174 to 205 nm when 
Fe3O4/PLGA weight ratio is increased between 1 and 20% wt/wt. On the other hand, at 
higher amounts of iron oxide nanoparticles, the distribution of the obtained composite 
PLGA nanoparticles was much broader or highly distorted (often having a second peak). 
The latter corresponded to another solid product differing from the HSA and iron-oxide-
containing PLGA nanoparticles. This precipitate was mainly composed of iron-oxide 
nanoparticles and also contained other unidentified materials, probably a mixture of 
PLGA, HSA and PVA. 
Fig. 4 a,b,c,d. 
Fig. 5. 
Both of the precisely non-identified precipitate containing iron oxide and the 
increase of PLGA nanoparticle size were obtained at high concentrations of iron oxide 
nanoparticles. This can be explained by the hydrophobic interactions between the oleic 
acid tails of Fe3O4 nanoparticles. These interactions are probably responsible for Fe3O4 
clustering (Astete et al. 2007) which explains the shifting of the mean particle size and 
size distribution towards the higher values. The latter explanation may be supported by 
the study Zhou et al. (Zhou et al. 2008) who studied the size of interferon loaded 
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magnetic PLA (Polylactic acid) and PLGA microspheres. The authors used Fe3O4 and 
found that size of both types of microspheres increased and the size distribution 
broadened with the increasing amounts of magnetic nanoparticles. On the other hand it is 
also expected that higher number of Fe3O4 nanoparticles inside the PLGA nanoparticles 
may adsorb more PLGA, which increases the amount of polymer in a particle, increasing 
its mass and size. 
The effect of Fe3O4 is also shown in Fig. 4(b)5 at different HSA concentrations in 
which the sonication time was 1 min longer than that in Fig. 4(a) (in Fig. 4(a) the time is 
2 minutes whereas in Fig. 4(b)5, it is 3 minutes). As a consequence of the latter, smallest 
mean particle size of the product expected at low iron oxide/PLGA weight ratio (1% 
wt/wt) was smaller, namely 180 nm. 
Effect of PLGA concentration 
As is seen in Fig. 4(a), particle size significantly increases with the increase in 
PLGA concentration. At medium HSA concentration (2.2% wt/vol), volume ratio of the 
intermediate and outer phases (4.0 vol/vol), sonication time (2.0 minutes), low 
magnetite/PLGA weight ratio (1.0% wt/wt), and the highest PLGA concentration (4.0% 
wt/vol), large PLGA particles of 223 nm volume mean size results as calculated by 
Eqn.1. By decreasing the concentration of PLGA in the organic phase to 1.0% wt/vol, the 
mean particle size decreases considerably to 174 nm while other four parameters were 
constant. 
The effect of PLGA concentration can also be observed in Fig. 7(d), discussed 
later in relation of the effect of sonication time. The explanation can be the change of 
rheological behavior of the mixture during the second emulsification. With the increase 
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in polymer concentration in the organic phase, its viscosity increases. High viscosity 
provides higher resistance against the shear forces during the second emulsification and 
restricts the formation of nanodroplets that are the basis of the formation of final 
composite PLGA nanoparticles. If cohesive forces in correlation with the viscosity and 
surface tension are higher in a liquid, it is more difficult to attain better dispersion by 
cavitation during ultrasonic treatment applied for emulsification. Therefore, high 
viscosity slows down the rapid dispersion of the polymer containing organic phase, 
which may considerably influence particle size. It means that insufficient dispersion of 
phases will result in larger particles with wide size distribution (Duan et al. 2006). If the 
viscosity of polymeric solution is high, it will slow down the rapid dispersion of organic 
phase into aqueous phase resulting in the formation of bigger droplets or aggregates 
(Kollipara et al. 2010). The viscous forces in the aqueous and organic phases oppose the 
shear stresses in the organic phase. Reducing the organic phase viscosity reduces the 
viscous forces which result in a net increase in shear stress felt by the organic phase. It 
decreases the PLGA nanoparticle size (Budhian et al. 2007). With an increase in the 
applied ultrasonic energy, it may be possible to overcome this viscosity problem. But too 
high sonication intensities can promote some undesired effects, such as analyte 
degradation. The increase in the particle size with the polymer concentration was 
observed by other authors with PLA (Chorny et al. 2002; Quintanar-Guerrero et al. 1996) 
or poly(lactide-co-glycolide) (Kwon et al. 2001). Devi Kusum et al. found that if drug to 
polymer (Acyclovir:PLGA) ratio increases from 1:1 to 1:2, particle size increases 
significantly and drug entrapment also increases (Kusum et al. 2009). It was also found 
by other researchers that for each solvent, above a critical concentration of polymer, large 
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amorphous polymer aggregates were formed in addition to the desired nanoparticles 
(Galindo-Rodriguez et al. 2004). Hence, use of polymer above a certain concentration is 
not beneficial. 
Effect of HSA concentration 
According to the Equation (1), also seen in Fig. 4(b)5, the HSA concentration in 
the inner aqueous phase has no significant effect on particle size. Because this protein 
was used as a model drug in this study, this is important information. However, apart 
from size, the concentration of HSA applied in the inner aqueous phase is essential in 
respect to  achieve desired drug concentration within the carrier NPs. Concentration of 
HSA also influences the efficiency of encapsulation i.e. the proportion of the utilized 
amount of model drug during the encapsulation process. The latter aspects will be 
discussed in our following paper (Part II). 
Effect of volume ratio of the W2 and O phases  
Volume ratio also has significant effect on the particle size as is seen on Fig. 
4(c)6. Namely, if the ratio between the volumes of external and internal phases of 
emulsion increases, particle size also increases. This finding is in agreement with the 
observation of other researchers, (Duan et al. 2006) who pointed out that this ratio play 
an important role influencing the stability of the emulsion and the size of dispersed 
globules.  
Fig. 6. 
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The basic principle governing the size of nanoparticles is that the external energy 
source (e.g. ultrasound energy) provides shear stresses to the internal organic phase, 
which results in the formation of nanodroplets, and finally nanoparticles from it. The size 
of the droplets is inversely correlated to the magnitude of shear stresses (Budhian et al. 
2007). Any change(s) in process variables or parameters that reduces these shear stresses 
will increase the nanoparticle size. The most direct influence on the shear stresses in the 
system is exercised by the energy density (external energy applied per unit total volume) 
(Budhian et al. 2007). Increase in energy density directly increases the shear stresses and 
results in more efficient droplet breakdown which will reduce the nanoparticle size. In 
our experiments, the introduced ultrasonic energy was constant for different volume 
ratios. The higher the volume ratio, the higher the liquid volume is which in turn reduces 
the available energy per unit volume, resulting in weaker emulsification. Weaker 
emulsification results in larger particles. 
From Fig. 4(c)6 (also confirmed by Equation 1), it can be found that volume ratio 
and magnetite/PLGA weight ratio have combined effect on mean size. It is seen that 
decrease in both the iron oxide/PLGA ratio and the volume ratio decrease the particle size 
very rapidly. This phenomenon can be well utilized for the production of very small 
nanoparticles, e.g. with mean size below 200 nm. 
Effect of sonication time 
From the Pareto chart, it can be seen that sonication time has the second strongest 
influence on particle size (just after PLGA concentration). Fig. 4(d)7 shows that particle 
size decreases greatly with the prolongation of sonication time. The reason is that 
increasing the power and/or the duration of sonication decreases the mean diameter of 
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nanoparticles, which may also change the population distribution. Higher power and/or 
longer duration of sonication increases the effect of shear stress and the energy causing 
more droplet breakdown, resulting in a decrease in particle size (Budhian et al. 2007). 
The great reduction of particle size is the consequence of stronger disintegration of 
droplets, due to the longer emulsification process (Feczko et al. 2011). Applying 
prolonged sonication (e.g. 3 minutes in our case), shear stress is acting for more time in 
the process leading to better dispersion of polymeric organic phase as nanodroplets of 
small size. On the contrary, short time of sonication, i.e. insufficient dispersion of phases 
results in large particles with wide size distribution. Mainardes and Evangelista et al. 
(Budhian et al. 2007) reported a decrease in particle diameter with increasing sonication 
time for PLGA nanoparticles system. 
Fig. 7. 
Prediction of the expected mean particle size 
As was seen in the discussion above on the effects of various process variables, 
the magnetite weight ratio to that of the polymer (PLGA) matrix, the concentration of 
PLGA in the intermediate organic phase, the volume ratio of the external aqueous and 
intermediate organic phases, and sonication time influenced the produced composite 
(model drug and magnetite loaded) nanoparticles. Knowing the exact values of these 
variables, the correlation obtained by linear regression (also considering the possibility of 
quadratic correlation and linear-linear interactions of variables, Eqn. 1), the mean particle 
size of the product can be predicted in a range of about 100 and 340 nm with a mean 
error of 27.6 nm, which is acceptable. Fig. 5(a)8 gives a comparison between the 
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measured and predicted mean particle sizes. It is seen that the measured and predicted 
values well correlate along the whole studied size interval.  The mean relative deviation 
between the measured and predicted values is 9.5% and the great majority of the data are 
within the +20% range (see dotted lines). However, along the studied size interval, there 
is slight tendency that in the lowest size region the predicted values are a bit 
overestimated whereas it is somewhat underestimated at the highest region. Considering 
that the aim is generally to achieve the smallest possible particle size, this tendency gives 
more safety than uncertainty.  
Fig. 5 a,b.8. 
Optimization of the process variables 
The formal model offered by the statistical evaluation in form of a regression 
equation (Eqn. 1), gives sufficient opportunity to find out the optimal conditions for 
producing NPs of required smallest mean particle size in the studied region. As was 
mentioned, small particle size is advantageous for different reasons e.g. sterilizing them 
by ultrafiltration is only eligible, if the size distribution does not exceed much above 220 
nanometer (the mean size in this case should be much lower, at least 130-160 nm). Small 
size of NPs is also required to avoid or reduce harmful interactions with the human 
organisms. To achieve this goal, the independent i.e. decision variables have to be set to 
optimal values in this respect. 
Optimization was relatively easy by the GAMS program package. The program 
showed that the optimal values of variables to get the smallest mean particle size were at 
the borders of their studied intervals. The optimal conditions were as follows: 
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magnetite/PLGA weight ratio, XFe3O4=1.0% wt/wt (the lowest value), PLGA 
concentration in the intermediate organic phase, XPLGA=1.0% wt/vol (the lowest value), 
volume ratio of the external aqueous phase to the intermediate organic phase XVOLR= 2.0 
vol/vol (the lowest value), time of second sonication Xtime=3.0 minutes (the highest 
value). The concentration of HSA in the inner aqueous phase had no influence in this 
relation, therefore it does not constrain process optimization. Under these conditions the 
predictable volume mean particle size is 132 nm, which is more than acceptable in 
respect of the properties for sterilization and utilization of the product NPs.  
Therefore, there is no special reason to use process variables outside the studied 
parameter intervals, which also may cause technical or economical difficulties (e.g. using 
too low PLGA concentration decreases the productivity of a given reaction vessel, or 
applying excessively long time of sonication may lead to degradation of the valuable 
drug substances). 
However, if the magnetite/PLGA ratio XFe3O4=1.0% wt/wt during encapsulation 
of the magnetic nanoparticles proves not to be sufficient to achieve suitable level of 
magnetism in the product NPs, it can be increased with the consequence of obtaining 
somewhat larger sizes. To clear up this consequence, optimization was carried out with 
constrain of different volume mean product particle sizes (this time not regarding the 
efficiencies of HSA and magnetite encapsulation). The results are shown in Fig. 5(b)9. In 
the diagram it is seen that the increase of magnetite/PLGA ratio causes a linear increase 
of the achievable mean particle size, providing optimal conditions regarding the best 
values of the three other decision variables (XPLGA=1.1% wt/vol, XVOLR= 2.0 vol/vol, 
Xtime=3.0 minutes). As a conclusion, if a mean particle size of 160 nm is allowed for the 
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sterilization by ultrafiltration and in respect of suitable properties as drug carrier, as high 
as 10% wt/wt magnetite/PLGA ratio can be applied to achieve suitable magnetic behavior 
of the product nanoparticles. 
Fig. 9. 
SUMMARY AND CONCLUSION 
Encapsulation of magnetite nanoparticles (MNPs) and human serum albumin 
(HSA) was carried out into the matrix of biocompatible polymer (PLGA) nanoparticles 
by double emulsion solvent evaporation method. Size distribution of prepared NPs was 
determined by using dynamic light scattering method. It was found that mean particle 
size was influenced by several process variables. To explore these effects a 5-factorial 3-
level experimental design and statistical analysis were carried out. 
As a summary of the effect of process variables on the mean hydrodynamic 
particle size of the produced HSA and magnetit -loaded PLGA nanoparticles, it was 
concluded that the concentration of PLGA in the intermediate organic phase and the 
duration of the second sonication have the strongest influences. The ratio of introduced 
magnetite nanoparticles relative to the weight of PLGA, the volume ratio of the external 
aqueous and intermediate organic phases, and the interaction of the latter with 
magnetite/PLGA ratio have also significant effect. To achieve the smallest possible mean 
particle size, relatively low PLGA concentration, high dispersion energy (enough 
sonication time) and relatively small volume ratio of the intermediate organic/external 
aqueous liquid should be applied. Low magnetite/PLGA weight ratio is also crucial but, 
from the utilization aspect, the former should be high enough to provide sufficient level 
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of magnetism to the produced nanoparticles by its encapsulation. The latter requirement 
leads to another study dealing with the efficacy of drug and magnetite encapsulation. The 
morphology of the PLGA NPs were studied by using scanning and transmission electron 
microscope (SEM, TEM) which showed that the prepared NPs were quite spherical.  The 
SEM and TEM images have been studied (therefore not included in the paper). 
Therefore it can be concluded, that the presence of magnetite nanoparticles does 
not have significant influence on the effect of other variable like polymer concentration, 
volume ratio of the external and intermediate phases, and the duration of sonication. This 
knowledge can help the process engineer to make the process well designable. 
Optimization of the process variables has been carried out in respect of obtaining 
the smallest possible mean particle size, allowed by the studied and reasonable intervals 
of the studied parameters. It was found that by a proper selection of four variables 
(magnetite/PLGA weight ratio XFe3O4, PLGA concentration in the intermediate organic 
phase XPLGA, volume ratio of the external aqueous phase to the intermediate organic 
phase XVOLR, and duration of the second sonication, Xtime) the volume mean particle size 
can be decreased to about 132 nm, which is beneficial for further processing and 
utilization of the product NPs. If, there is constraint in respect of magnetite/PLGA ratio, 
i.e. if higher iron oxide/PLGA weight ratio needed to be applied to achieve sufficient 
level of magnetism, the minimum achievable mean particle size increases but, in the 
worst case, it remains below 160 nm even using a magnetite/PLGA weight ratio as high 
as 10.0% wt/wt. 
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NOMENCLATURE 
Variables 
Dmean mean hydrodynamic particle size, nm 
XFe3O4 Weight ratio of the introduced magnetite compared to the mass of PLGA, 
% wt/wt 
XPLGA Concentration of PLGA in the intermediate oil phase, % wt/vol 
XHSA Concentration of HSA in the inner aqueous phase, % wt/vol  
XVOLR Volume ratio of the outer aqueous phase to the intermediate oily phase, 
vol/vol  
Xtime Time of the second sonication, minute 
Other notations and indices 
C Central point of the studied interval of all independent variables 
F1, F2, F3, 
F4, F5 
Factors (independent variables) 
L Indication of the linear effect of a given variable (factor) 
FiLbyFjL Effect of linear-linear interaction between the factors Li and Lj   
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O oily phase (intermediate phase) of the emulsion 
W, W2 Aqueous phase, the second (outer) aqueous phase of the emulsion 
F Result of the statistical F test on the studied variable (in ANOVA table) 
p Statistical significance level (in ANOVA table) 
df Degree of freedom (in ANOVA table) 
MS Mean square of the residuals, nm2 (in ANOVA table) 
SS Sum of deviation squares, nm2 (in ANOVA table) 
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Legends of Figures 
Fig. 1. Encapsulation of model drug loaded magnetic PLGA nanoparticles using double 
emulsion solvent evaporation method. 
Fig. 2.  Typical size distributions of the PLGA nanoparticles obtained with different 
process variables: a – small, b – medium, and c – relatively high size region.      
Fig. 3. Pareto chart on the standardized effects of the independent process variables on 
the mean hydrodynamic particle size. 
Fig. 4. The effect of various process variables on the mean particle size; fixed parameters: 
(a) Fe3O4/PLGA weight ratio and PLGA concentration (b) HSA concentration and 
Fe3O4/PLGA weight ratio (c) volume ratio and Fe3O4/PLGA weight ratio (d) PLGA 
concentration and sonication time.on the mean particle size. 
Fig. 5. The effect of HSA concentration and Fe3O4/PLGA weight ratio on the mean 
particle size. 
Fig. 6. The effect of volume ratio and Fe3O4/PLGA weight ratio on the mean particle 
size. 
Fig. 7. The effect of PLGA concentration and sonication time on the mean particle size. 
Fig. 58. (a) Ccomparison of the measured and predicted mean particle sizes (b) smallest 
achievable mean particle size with constrain of various magnetite/ PLGA ratios at 
optimized other process variables. 
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Fig. 9.  The smallest achievable mean particle size with constrain of various magnetite/ 
PLGA ratios at optimized other process variables. 
Legends of Tables 
Table 1. Process variables (factors) used in experimental design and their studied ranges. 
Table 2. Result of statistical analysis on the dependence of the measured mean particle 
sizes as a function of the influencing factors (ANOVA table). 
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Fig. 1. Encapsulation of model drug loaded magnetic PLGA nanoparticles using double emulsion solvent 
evaporation method  
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Fig. 2.  Typical size distributions of the PLGA nanoparticles obtained with different process variables: a – 
small, b – medium, and c – relatively high size region  
46x13mm (300 x 300 DPI)  
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Fig. 3. Pareto chart on the standardized effects of the independent process variables on the mean 
hydrodynamic particle size  
596x464mm (96 x 96 DPI)  
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Fig. 4. The effect of various process variables on the mean particle size; fixed parameters: (a) Fe3O4/PLGA 
weight ratio and PLGA concentration (b) HSA concentration and Fe3O4/PLGA weight ratio (c) volume ratio 
and Fe3O4/PLGA weight ratio (d) PLGA concentration and sonication time  
1048x825mm (96 x 96 DPI)  
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Fig. 5. (a) comparison of the measured and predicted mean particle sizes (b) smallest achievable mean 
particle size with constrain of various magnetite/ PLGA ratios at optimized other process variables  
1016x396mm (96 x 96 DPI)  
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Table 1 
Process variables (factors) used in experimental design and their studied ranges. 
 
Factor Symbol Variable Studied intervals 
 
F1 XFe3O4 Fe3O4/PLGA weight ratio  1-20 wt%  
F2 XPLGA PLGA concentration in the organic phase 1-4 wt% 
F3 XHSA HSA concentration in the inner aqueous phase 0.74-3.69 wt% 
F4 XVOLR Outer aqueous (w2)/organic phase (o) ratio volume 
ratio. 
2-6 vol/vol 
F5 Xtime Time of the ultrasonic treatment in the second 
emulsification 
1-3 minutes 
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Table 2 
Result of statistical analysis on the dependence of the measured mean particle sizes as a 
function of the influencing factors (ANOVA table). 
 
Factor 
ANOVA; Var.:Mean particle size, nm 
5 3-level factors, 90 Runs; MS Residual=762.4 
Mean error=27.6 nm 
SS 
 
df MS F p 
F1 Fe3O4 conc. (L) 12343.9 1 12343.89 16.19139 0.000125 
F2 PLGA conc. (L) 31447.1 1 31447.08 41.24891 0.000000 
F4 Volume ratio W2/O (L) 4183.7 1 4183.68 5.48771 0.021516 
F5 Time of sonication, min (L) 18699.7 1 18699.73 24.52829 0.000004 
interaction F1L by F4L 7898.1 1 7898.09 10.35987 0.001831 
Error 
 
64039.4 84 762.37   
Total SS 138611.9 89    
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Appendix A  
Experimental program obtained by 5-factorial 3-level experimental design with the applied 
process variables (factors), and the measured mean particle sizes and encapsulation 
efficiencies 
Run # after 
randomization 
of their order 
F1 
(Fe3O4/PLGA 
weight ratio),  
wt/wt% 
F2 
(PLGA 
conc.), 
wt/vol% 
F3  
(HSA 
conc.), 
wt/vol% 
F4 
(Volume 
ratio 
W2/O), 
vol/vol 
F5  
(Time of 
sonication), 
min 
Mean 
particle 
size, nm 
Encapsulation 
efficiency, % 
10 1.0 4.0 0.74 6.0 3.0 175.6 90.40 
83 (C) 10.5 2.5 2.21 4.0 2.0 203.3 91.77 
18 10.5 4.0 0.74 4.0 3.0 221.7 92.80 
1 20.0 4.0 2.21 4.0 1.0 197.6 94.40 
26 1.0 1.0 0.74 2.0 1.0 162.8 82.40 
16 10.5 4.0 3.69 2.0 2.0 238.2 95.66 
19 20.0 2.5 3.69 4.0 1.0 228.0 73.24 
9 1.0 4.0 2.21 2.0 1.0 220.7 96.32 
11 10.5 2.5 0.74 2.0 2.0 198.5 91.24 
25 1.0 2.5 2.21 6.0 3.0 193.3 92.40 
17 20.0 1.0 3.69 2.0 3.0 225.5 53.98 
13 20.0 4.0 0.74 2.0 3.0 210.6 94.30 
2 20.0 2.5 0.74 6.0 2.0 210.3 87.60 
3 10.5 2.5 3.69 6.0 1.0 291.2 83.48 
24 1.0 2.5 3.69 2.0 1.0 156.2 72.20 
15 10.5 1.0 2.21 2.0 2.0 121.8 64.50 
5 1.0 1.0 2.21 4.0 2.0 114.9 72.60 
12 1.0 1.0 3.69 6.0 3.0 139.6 33.82 
84 (C) 10.5 2.5 2.21 4.0 2.0 250.3 90.23 
6 10.5 1.0 0.74 6.0 1.0 258.6 81.01 
21 1.0 2.5 0.74 4.0 2.0 206.4 88.66 
14 20.0 1.0 2.21 6.0 2.0 205.2 74.59 
4 10.5 2.5 2.21 4.0 3.0 189.9 85.71 
22 10.5 1.0 3.69 4.0 3.0 149.0 60.86 
8 20.0 4.0 3.69 6.0 2.0 253.3 79.50 
7 10.5 4.0 2.21 6.0 1.0 233.2 90.05 
23 20.0 1.0 0.74 4.0 1.0 212.6 72.96 
20 20.0 2.5 2.21 2.0 3.0 224.5 87.88 
82 (C) 10.5 2.5 2.21 4.0 2.0 206.0 82.00 
27 1.0 4.0 3.69 4.0 2.0 212.7 86.68 
34 10.5 4.0 3.69 4.0 1.0 234.3 92.70 
51 10.5 1.0 2.21 4.0 1.0 207.6 85.30 
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43 10.5 2.5 0.74 4.0 1.0 232.0 97.20 
30 10.5 1.0 0.74 2.0 3.0 171.9 83.50 
46 20.0 2.5 3.69 6.0 3.0 225.7 84.10 
38 1.0 2.5 0.74 6.0 1.0 239.8 78.90 
36 10.5 4.0 2.21 2.0 3.0 203.0 94.40 
44 1.0 4.0 0.74 2.0 2.0 201.4 91.00 
39 1.0 4.0 2.21 4.0 3.0 219.1 86.40 
28 20.0 1.0 3.69 4.0 2.0 195.1 36.32 
49 20.0 4.0 3.69 2.0 1.0 308.1 90.20 
85 (C) 10.5 2.5 2.21 4.0 2.0 214.2 86.40 
29 20.0 1.0 2.21 2.0 1.0 207.1 33.54 
41 10.5 2.5 3.69 2.0 3.0 196.1 49.50 
40 1.0 2.5 3.69 4.0 3.0 178.4 81.30 
54 1.0 2.5 2.21 2.0 2.0 169.8 90.50 
50 1.0 1.0 0.74 4.0 3.0 138.1 79.39 
48 20.0 2.5 2.21 4.0 2.0 233.8 92.50 
52 20.0 2.5 0.74 2.0 1.0 236.0 91.22 
86 (C) 10.5 2.5 2.21 4.0 2.0 213.8 89.17 
45 20.0 4.0 0.74 4.0 2.0 217.9 88.42 
32 20.0 1.0 0.74 6.0 3.0 180.6 67.20 
47 10.5 1.0 3.69 6.0 2.0 192.0 50.69 
42 10.5 2.5 2.21 6.0 2.0 229.5 85.30 
35 1.0 1.0 2.21 6.0 1.0 240.3 55.80 
33 1.0 4.0 3.69 6.0 1.0 287.4 88.80 
31 1.0 1.0 3.69 2.0 2.0 219.1 18.21 
53 20.0 4.0 2.21 6.0 3.0 222.4 65.91 
37 10.5 4.0 0.74 6.0 2.0 235.0 87.50 
87 (C) 10.5 2.5 2.21 4.0 2.0 209.1 79.40 
63 1.0 4.0 2.21 6.0 2.0 286.9 89.78 
88 (C) 10.5 2.5 2.21 4.0 2.0 214.2 81.10 
55 20.0 1.0 3.69 6.0 1.0 211.0 43.42 
81 1.0 1.0 2.21 2.0 3.0 123.1 43.79 
70 1.0 2.5 0.74 2.0 3.0 169.9 85.50 
66 10.5 2.5 3.69 4.0 2.0 199.7 80.30 
71 10.5 2.5 0.74 6.0 3.0 241.7 89.58 
72 20.0 4.0 2.21 2.0 2.0 328.9 91.80 
79 20.0 2.5 0.74 4.0 3.0 206.1 82.60 
67 20.0 4.0 3.69 4.0 3.0 258.7 87.20 
64 1.0 1.0 0.74 6.0 2.0 165.5 74.50 
61 10.5 4.0 2.21 4.0 2.0 235.1 89.90 
78 10.5 1.0 2.21 6.0 3.0 213.8 81.70 
90 (C) 10.5 2.5 2.21 4.0 2.0 205.1 87.60 
58 1.0 2.5 2.21 4.0 1.0 231.1 84.17 
75 20.0 2.5 3.69 2.0 2.0 304.8 34.84 
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57 10.5 1.0 0.74 4.0 2.0 226.2 77.50 
80 1.0 1.0 3.69 4.0 1.0 244.8 33.28 
62 1.0 4.0 3.69 2.0 3.0 201.1 87.47 
74 1.0 2.5 3.69 6.0 2.0 225.0 83.24 
69 1.0 4.0 0.74 4.0 1.0 246.3 91.80 
76 20.0 2.5 2.21 6.0 1.0 273.2 88.10 
73 20.0 4.0 0.74 6.0 1.0 259.2 81.17 
56 20.0 1.0 2.21 4.0 3.0 150.7 74.59 
59 20.0 1.0 0.74 2.0 2.0 199.2 83.45 
77 10.5 1.0 3.69 2.0 1.0 177.3 39.39 
65 10.5 4.0 0.74 2.0 1.0 238.1 94.03 
68 10.5 2.5 2.21 2.0 1.0 210.6 92.04 
60 10.5 4.0 3.69 6.0 3.0 210.3 87.60 
89 (C) 10.5 2.5 2.21 4.0 2.0 208.0 88.90 
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